CHAT GPT 5.5
Here is the comparison I would use. My bottom line: the 2023 article is a technical reimbursement primer with some advocacy ambitions; the 2026 article is a much shorter but more institutional “we are organizing for battle” statement. It does look like a restart, but the restart is more about governance, policy capacity, and payer-facing evidence strategy than about new technical reimbursement theory.
The two articles
2023: Pathways to Direct Reimbursement for Slide Digitization and Digital Pathology/AI Technologies — posted 10/10/2023 by the DPA Reimbursement Task Force.
2026: Full Speed Ahead: Shaping the Future of Digital Pathology Reimbursement in 2026 — posted 04/06/2026 by the DPA Reimbursement Task Force.
https://digitalpathologyassociation.org/blog/author/id/66
High-level contrast
The 2023 article is reimbursement-mechanics heavy. It begins with the then-current and upcoming Category III slide digitization codes, explains why they had no payment rate, and warns that converting Category III codes to Category I codes may be neither fast nor necessarily sufficient. But it is not only about Category III codes. It also discusses CMS authority to price Category III codes, CMS divergence from AMA/RUC valuation, OPPS treatment of AI/software add-on codes, and the awkward interaction between AMA CPT codes and CMS-created HCPCS codes such as G0416 for prostate biopsies.
The 2026 article is much less a coding tutorial and much more a mobilization statement. It frames reimbursement as a critical barrier to adoption, states a DPA mission to “define and shape” reimbursement pathways, highlights a pending AI validation/implementation recommendation statement, and announces a strategic partnership with McDermott+ to monitor and influence CMS, AMA, Congress, and other policymakers.
What the 2023 article was really saying
The 2023 piece was not naïve about Category III codes. In fact, it was surprisingly nuanced. It acknowledged that 43 digital pathology Category III codes would soon exist, but that they had no national payment rates and that CMS and payer perception of the codes remained unclear. It emphasized that one rationale for using the codes was to demonstrate utilization, creating a data trail that might support eventual Category I coding.
But the article also warned against assuming that Category I conversion was the magic door. It noted that Category III codes can be paid locally, that Category I codes may not get better rates, and that CMS—not AMA—ultimately controls Medicare payment. The article gave examples where CMS created national payment rates for Category III codes, ignored or modified RUC recommendations, created alternative HCPCS Level II codes, or used OPPS payment logic for AI/software services.
So, while the headline emphasis was slide digitization Category III codes, the deeper message was broader: digital pathology should not put all its chips on the AMA/RUC/Category I pathway. CMS has multiple routes to recognition and payment, but stakeholders must bring data, valuation evidence, and advocacy.
What the 2026 article adds
The 2026 article does not revisit the technical coding map in detail. Instead, it shifts from “here are the possible payment pathways” to “here is the infrastructure we are building to act on them.”
Two elements stand out.
First, DPA links reimbursement to a formal evidence strategy. The article describes a pending recommendation statement for validation, implementation, and clinical application of AI in the clinical laboratory. DPA frames this as both a clinical roadmap and a payer-facing evidence base: labs need a standardized blueprint, and payers need proof that AI is safe, validated, and essential for patient care.
Second, DPA announces the McDermott+ partnership. This is the clearest difference from 2023. In 2023, the Task Force said it was initiating CMS engagement and would comment on CMS and MAC policies. In 2026, DPA says it has hired specialized Washington policy capacity to monitor CMS, AMA, Congress, and other decision-makers and to make DPA an “active and recognized stakeholder” through official comment and direct agency engagement.
That is a materially different posture. It is no longer just “the community should understand reimbursement pathways.” It is “DPA intends to shape them.”
Continuity between 2023 and 2026
There is real continuity. Both articles identify reimbursement as a barrier to adoption. Both are issued by the DPA Reimbursement Task Force. Both see CMS and AMA policy as central. Both argue that the digital pathology community must generate evidence and engage policymakers.
The 2023 article already closed with a pledge that DPA would contribute actively to reimbursement momentum and build a unified advocacy effort. The 2026 article essentially says: that effort now has a public mission statement, an AI-evidence publication strategy, and outside policy counsel.
Key difference in tone
The tone is strikingly different.
The 2023 tone is cautious, lawyerly, and explanatory. It is full of caveats: Category III may help, Category I may not be enough, CMS may or may not assign payment, stakeholders must provide data, and multiple pathways exist.
The 2026 tone is promotional and action-oriented. Phrases like “Full Speed Ahead,” “North Star,” “not a year for wait and see,” and “tangible, measurable progress” give the article the feel of an organizational relaunch. It is not a detailed policy memo; it is a signal to members and external stakeholders that DPA intends to be more visible and organized.
My clean blog-ready interpretation
A fair way to say it:
DPA’s October 2023 reimbursement article was a sophisticated but technical map of possible payment pathways, centered on the then-new Category III slide digitization codes but extending into CMS authority, HCPCS alternatives, OPPS software payment, and the need for valuation data. The April 2026 article is different. It is shorter, less technical, and more strategic. Rather than explaining the maze, it announces that DPA is building the machinery to navigate it: a validation/evidence statement for AI, a more explicit reimbursement mission, and a policy partnership with McDermott+ to engage CMS, AMA, Congress, and other decision-makers. In that sense, the 2026 piece reads less like a reimbursement tutorial and more like an organizational reboot.
###
SIDEBAR - Membership
The Reimbursement Committee at DPA ( Membership, $100/yr) has 25 members and two co-chairs. in sharp contrast to reimbursement or leadership councils at AMP or CAP, only a couple of the committee members are in academics rather than business. (Businesses incllude Roche, Leica, Proscia, Hologic, Astrazeneca, etc).
###
CLAUDE OPUS 4.8
###
Both pieces carry the same byline ("DPA Reimbursement Task Force") and invoke the same premise — reimbursement is the gating barrier to adoption — but they are different genres written for different purposes, and reading them back-to-back tells you more about strategy than either does alone.
At a glance
| Dimension |
Oct 2023 |
Apr 2026 |
| Genre |
Analytical white paper (≈6 pp + 6 figures) |
Membership newsletter / advocacy update (≈1.5 pp) |
| Center of gravity |
Slide digitization (WSI creation) |
AI (algorithm validation) |
| Core argument |
Contrarian: Cat I conversion is "neither necessary nor sufficient"; CMS has alternative pathways |
Aspirational: momentum, evidence-building, professionalized advocacy |
| Flagship deliverable |
Intellectual: a map of CMS payment mechanics |
Two assets: a submitted AI validation statement + a McDermott+ retainer |
| Evidentiary style |
No citations, dense with checkable regulatory specifics (code numbers, APCs, rulings, years) |
Two academic citations (Zarella 2023, Bessen 2025), otherwise assertion |
| Posture |
Teaching / diagnosing |
Reassuring / recruiting |
| Tone |
Dry, technical, skeptical of consensus |
"Full Speed Ahead," "North Star," "Forward together" |
What the 2023 piece actually was
It's easy to file the 2023 article as "the Cat III piece," but its intellectual core was heretical for its moment.
The stakeholder consensus then — and arguably now — was that the path to payment ran through converting the 43 slide-digitization Category III add-on codes into Category I codes with RUC-set RVUs. The Task Force, in 2023, quietly argued the opposite: that Cat I is neither necessary nor sufficient, that conversion carries real downside (years-long timelines, the 5-year archive guillotine, the risk that a revised Cat I descriptor lands at the same payment with nothing added for digitization, contagion to the rest of the code family, and loss of MAC local-pricing flexibility), and that CMS has repeatedly paid by other routes entirely. It then enumerated those routes with specificity — national rates set directly on Cat III codes (glucose 0446–0448T, HeartFlow FFR 0503T, ERG 0509T); CMS overriding the RUC on valuation (the HeartFlow consolidation to a single Cat I code with a technical component crosswalked back to the 2018 OPPS price); OPPS "Software as a Service" add-on parity (Liver Multi-Scan, Optellum, QMRCP, with the 0648T/0649T standalone-plus-add-on structure as the template); and CMS bypassing the AMA altogether via HCPCS Level II (G0416 for prostate biopsy, whose missing add-on is the reason digitization can't be captured on those claims).
[BQ CMS had bypassed RUC several times, but reluctantly and these were viewed as rare high-touch workarounds awaiting a long term and scaleable fix]
That is a genuinely sophisticated document. It is teaching the reader how the machine works and, implicitly, telling them the field had picked the wrong lever.
What the 2026 piece is — and what's missing
The 2026 article contains none of that. The codes aren't mentioned. The payment mechanics aren't mentioned. The alternative-pathway thesis — the most original thing the Task Force had published — has vanished.
In its place are two items, both of which are inputs rather than outcomes: a recommendation statement on AI validation that has been submitted (not published, "in the review phase"), [silverburg now published June] and a signed consulting engagement with McDermott+.
This is the analytically important point, and it's where I'd gently push on the defibrillator framing you offered. [I joked 2026 was like a defib ER reboot of 2023's motionless body.] A defibrillator restarts the same rhythm. What 2026 shows is closer to a restart on a different operating model. The 2023 strategy was bottom-up code engineering — get the codes, generate utilization, feed CMS RUC-like cost data, exploit the alternative pathways. The 2026 strategy is top-down — build a clinical/evidentiary foundation (the AI statement) and buy sustained Washington access (the lobbying firm). Read uncharitably, the silence between them plus the quiet abandonment of the coding-mechanics narrative is a tacit concession that the 2023 approach didn't convert: the Cat III codes were, as you put it, ill-fated — no rates, unclear uptake — and the Task Force has stopped litigating that problem in public and pivoted to firmer ground.
So the heart did get jolted back, but it woke up with a new care plan. And notice what a victory lap would have looked like and isn't here: no new code, no payment rate secured, no LCD, no reported CMS response to the 2023 "meeting this quarter," no status update on the 43 codes.
For a Task Force whose 2023 piece promised "regular updates" and imminent agency engagement, the 30-month flatline is itself data, and "Full Speed Ahead" is doing a lot of rhetorical work over a re-launch from roughly zero.
The drift that should matter to you specifically
The most consequential shift for a Leica/Danaher read is the migration of the subject: from digitization to AI. The 2023 piece is fundamentally about paying for the scan — the act of turning glass into a WSI, which is Leica's (Aperio's) core business and the unglamorous foundation everything else sits on. The 2026 flagship deliverable is about validating algorithms in the clinical lab — the application layer where Paige, PathAI, and the pure-play AI vendors live.
That drift tracks where FDA/CMS attention and perceived novelty-value have moved, and it's defensible as advocacy positioning. But it arguably leaves the boring, vendor-critical question — who pays for the digitization itself, and through what code structure — unaddressed in the very document that should own it. If you're advising Leica, the watch-item is whether the DPA's reimbursement agenda is quietly becoming an AI-reimbursement agenda, in which the scanner-and-platform layer is assumed rather than funded. A whole-slide image with no payment path doesn't become more reimbursable because an algorithm later reads it.
Net
There's real continuity — same byline, same "reimbursement is the barrier" premise, same CMS/AMA advocacy posture (the 2023 piece already described comment letters and CMS meetings, so the posture isn't new; its professionalization and funding via McDermott+ is). The McDermott+ engagement is a genuine maturation signal worth taking seriously. But on substance, 2026 is thinner, more promotional, and strategically narrower-but-different than its predecessor. The 2023 piece was the smarter document; the 2026 piece is the better-funded one. Whether that trade pays off depends entirely on outputs the April article conspicuously cannot yet point to.
If it'd be useful, I can pull the DPA blog archive to confirm whether anything reimbursement-related actually ran between these two posts, or check the current status of the AI validation statement and the 43 Cat III codes — that would let us test the "flatline" read against the record rather than inferring it from the two documents alone.
